The microbiome in our digestive system plays a crucial role in maintaining a healthy
balance and preventing diseases. Any imbalance in the microbiome, called dysbiosis,
can increase the risk of sepsis and lead to a poor response to infection in the body.
This review provides an overview of this topic's extent, range, and nature by clarifying
the gaps in current knowledge and planning for future works. Our research involved
identifying clinical trials that administered biotics to adult patients with sepsis.
We thoroughly reviewed the studies to determine if any harm was caused to the microbiome
during sepsis treatment. In addition, we explored other literature to gain insights
into the relationship between the microbiome and sepsis. Our findings indicate that
biotic products have been used in treating septic patients in only three studies.
The studies varied in terms of conditions, assessed outcomes, populations, and products
administered. To ensure the patient's well-being and avoid complications, treatment
strategies for sepsis should prioritize maintaining a balanced microbiome and avoiding
dysbiosis. Maintaining a healthy microbiome is not just about taking probiotic supplements.
A deeper understanding of complex concepts like organ interaction and epigenetic modification
can help understand the connection between the microbiome and sepsis, which could
lead to new avenues of research. However, this is still a difficult task, and further
clinical trials are needed to explore this area.
